219 related articles for article (PubMed ID: 12569375)
21. C-reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Hamano I; Fujita N; Yoneyama T; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Int J Urol; 2019 Oct; 26(10):992-998. PubMed ID: 31342557
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
[TBL] [Abstract][Full Text] [Related]
23. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
[TBL] [Abstract][Full Text] [Related]
24. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
25. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.
Guida M; Casamassima A; Monticelli G; Quaranta M; Colucci G
J Transl Med; 2007 Oct; 5():51. PubMed ID: 17953739
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J; Kirchner H; Rebmann U; Soder M; Gertenbach U; Siebels M; Roigas J; Raschke R; Salm S; Schwindl B; Müller SC; Hauser S; Leiber C; Huland E; Heinzer H; Siemer S; Metzner B; Heynemann H; Fornara P; Reitz M
Br J Cancer; 2006 Aug; 95(4):463-9. PubMed ID: 16909131
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Ku JH
Tumori; 2007; 93(1):68-74. PubMed ID: 17455874
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma.
Hoffmann R; Franzke A; Buer J; Sel S; Oevermann K; Duensing A; Probst M; Duensing S; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1999 Apr; 79(11-12):1742-5. PubMed ID: 10206286
[TBL] [Abstract][Full Text] [Related]
31. Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2006 Jun; 21(3):206-10. PubMed ID: 16918296
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution.
Libra M; Talamini R; Crivellari D; Buonadonna A; Freschi A; Stefanovski P; Berretta M; De Cicco M; Balestreri L; Merlo A; Volpe R; Galligioni E; Sorio R
Tumori; 2003; 89(4):400-4. PubMed ID: 14606643
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
[TBL] [Abstract][Full Text] [Related]
34. Predicting survival of patients with metastatic renal cell carcinoma.
Motzer RJ; Mazumdar M
Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
[TBL] [Abstract][Full Text] [Related]
35. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.
Atzpodien J; Kirchner H; Hänninen EL; Deckert M; Fenner M; Poliwoda H
Eur J Cancer; 1993; 29A Suppl 5():S6-8. PubMed ID: 8260264
[TBL] [Abstract][Full Text] [Related]
37. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
[TBL] [Abstract][Full Text] [Related]
38. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
39. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T
N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
